[Federal Register Volume 79, Number 164 (Monday, August 25, 2014)]
[Notices]
[Pages 50658-50659]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-20017]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2014-N-0001]


Advisory Committee Renewals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
renewal of certain FDA advisory committees by the Commissioner of Food 
and Drugs (the Commissioner). The Commissioner has determined that it 
is in the public interest to renew the

[[Page 50659]]

charters of the committees listed in the following table for an 
additional 2 years beyond charter expiration date. The new charters 
will be in effect until the dates of expiration listed in the following 
table.

DATES: Authority for these committees will expire on the dates 
indicated in the following table unless the Commissioner formally 
determines that renewal is in the public interest.

------------------------------------------------------------------------
             Name of committee                   Date of expiration
------------------------------------------------------------------------
Advisory Committee for Pharmaceutical       January 22, 2016.
 Science and Clinical Pharmacology.
Gastrointestinal Drugs Advisory Committee.  March 3, 2016.
Bone, Reproductive and Urologic Drugs       March 23, 2016.
 Advisory Committee (formerly Reproductive
 Health Drugs Advisory Committee).
                                            April 5, 2016.
Arthritis Advisory Committee..............  April 25, 2016.
Pharmacy Compounding Advisory Committee...  May 1, 2016.
Anesthetic and Analgesic Drugs Advisory     May 13, 2016.
 Committee.
Blood Products Advisory Committee.........  May 30, 2016.
Pulmonary-Allergy Drugs Advisory Committee  May 31, 2016.
Drug Safety and Risk Management Advisory    June 2, 2016.
 Committee.
Science Advisory Board to the National      June 4, 2016.
 Center for Toxicological Research.
Peripheral and Central Nervous System       June 4, 2016.
 Drugs Advisory Committee.
Psychopharmacologic Drugs Advisory          June 9, 2016.
 Committee.
Transmissible and Spongiform                June 26, 2016.
 Encephalopathies Advisory Committee.
Science Board to the Food and Drug          July 9, 2016.
 Administration.
Allergenic Products Advisory Committee....
------------------------------------------------------------------------


FOR FURTHER INFORMATION CONTACT: Michael Ortwerth, Director, Advisory 
Committee Oversight and Management Staff, Food and Drug Administration, 
10903 New Hampshire Ave., Silver Spring, MD 20993-0002, 301-443-0572 or 
1-800-741-8138. For further information related to FDA advisory 
committees please visit us at: http://www.fda.gov/AdvisoryCommittees/default.htm.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2).

    Dated: August 19, 2014.
Peter Lurie,
Associate Commissioner for Policy and Planning.
[FR Doc. 2014-20017 Filed 8-22-14; 8:45 am]
BILLING CODE 4164-01-P